

Thomas John

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8808239/thomas-john-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97
papers

3,519
citations

27
h-index

58
g-index

114
ext. papers

4,883
ext. citations

6.1
avg, IF

5.27
L-index

#	Paper	IF	Citations
97	Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020 , 382, 41-50	59.2	771
96	Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 841-849	2.2	291
95	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 198-211	21.7	244
94	Molecular predictive and prognostic markers in non-small-cell lung cancer. <i>Lancet Oncology</i> , 2009 , 10, 1001-10	21.7	167
93	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 134-41	12.9	131
92	Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. <i>Cancer Cell</i> , 2013 , 23, 618-33	24.3	107
91	Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1728-1732	8.9	99
90	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3591-3600	2.2	93
89	Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. <i>Clinical Epidemiology</i> , 2014 , 6, 423-32	5.9	90
88	Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 461-8	8.9	87
87	Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9501-9501	2.2	87
86	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. <i>Cell Death and Disease</i> , 2019 , 10, 342	9.8	81
85	Distinctive localization of antigen-presenting cells in human lymph nodes. <i>Blood</i> , 2009 , 113, 1257-67	2.2	65
84	The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 850-859	8.9	64
83	Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1635-46	7.4	62
82	Predicting clinical outcome through molecular profiling in stage III melanoma. <i>Clinical Cancer Research</i> , 2008 , 14, 5173-80	12.9	58
81	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1784-1791	8.9	57

80	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. <i>Lancet Respiratory Medicine, the</i> , 2017 , 5, 891-902	35.1	56
79	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology, The</i> , 2020 , 21, 1213-1223	21.7	53
78	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. <i>PLoS ONE</i> , 2016 , 11, e0153954	3.7	53
77	Understanding prognostic gene expression signatures in lung cancer. <i>Clinical Lung Cancer</i> , 2009 , 10, 331-40	4.9	49
76	Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1513-21	8.9	41
75	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9512-9512	2.2	41
74	Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1101-8	8.9	34
73	Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017 , 23, 1060-1067	12.9	32
72	Pharmacogenetic and germline prognostic markers of lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 296-304	8.9	31
71	A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. <i>Scientific Reports</i> , 2014 , 4, 4186	4.9	27
70	The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. <i>PLoS ONE</i> , 2013 , 8, e67876	3.7	25
69	ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 3291-8	12.9	25
68	Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Immunotherapy</i> , 2016 , 39, 202-4	5	25
67	Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. <i>Lung Cancer</i> , 2016 , 98, 29-32	5.9	24
66	Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1588-1594	8.9	23
65	Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. <i>Cancer Medicine</i> , 2013 , 2, 916-24	4.8	22
64	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. <i>Lung Cancer</i> , 2017 , 107, 22-35	5.9	21
63	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2018 , 126, 133-138	5.9	21

62	Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine. <i>Oncotarget</i> , 2014 , 5, 2107-15	3.3	18
61	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 142, 34-40	5.9	16
60	Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. <i>International Journal of Cancer</i> , 2014 , 135, 1842-51	7.5	16
59	Do randomized acupuncture studies in patients with cancer need a sham acupuncture control arm?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2057-8	2.2	15
58	Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. <i>Genome Medicine</i> , 2012 , 4, 84	14.4	14
57	Current and Evolving Methods to Visualize Biological Data in Cancer Research. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	13
56	Vortex Keratopathy Presumed Secondary to AZD9291. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1807-8	8.9	13
55	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 296-303	1.9	12
54	Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8514-8514	2.2	11
53	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2117-2125	6.1	11
52	Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. <i>Pathology</i> , 2016 , 48, 660-665	1.6	10
51	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with Fusion-Positive Solid Tumors.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	10
50	Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 74036-74048	3.3	10
49	Immunotherapy of advanced or metastatic melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 994-1006	0.6	10
48	Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma. <i>Expert Opinion on Drug Delivery</i> , 2019 , 16, 441-451	8	9
47	NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 146, 154-159	5.9	9
46	Lung cancer in 2016: immunotherapy comes of age. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 947-949	35.1	9
45	"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. <i>Journal of Personalized Medicine</i> , 2015 , 5, 354-69	3.6	8

44	BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2020 , 6, 114	6.9	8
43	Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1677-8; author reply 1678-9	9.7	7
42	Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. <i>Translational Lung Cancer Research</i> , 2020 , 9, 639-645	4.4	7
41	Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report. <i>Journal of Medical Case Reports</i> , 2012 , 6, 261	1.2	6
40	Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. <i>Translational Lung Cancer Research</i> , 2020 , 9, 360-365	4.4	6
39	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e859-e869	4.9	6
38	Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 1235-1245	3.5	6
37	Standard dose osimertinib for erlotinib refractory T790M-negative -mutant non-small cell lung cancer with leptomeningeal disease. <i>Journal of Thoracic Disease</i> , 2019 , 11, 1756-1764	2.6	5
36	Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 924, 139-146	3.6	5
35	A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2021 , 7, 122	6.9	5
34	Standard of care in immunotherapy trials: Challenges and considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 2164-2178	4.4	4
33	Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	4
32	Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. <i>Translational Lung Cancer Research</i> , 2019 , 8, 167-175	4.4	4
31	Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results. <i>Clinical Lung Cancer</i> , 2021 , 22, 74-82	4.9	4
30	The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 413-424	3.5	4
29	Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer. <i>Head and Neck</i> , 2017 , 39, 1544-1549	4.2	3
28	Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015 , 11 Suppl 1, 2-8	1.9	3
27	Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. <i>Lung Cancer</i> , 2020 , 150, 1-8	5.9	3

26	De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer. <i>Internal Medicine Journal</i> , 2017 , 47, 1071-1074	1.6	3
25	Ventricular metastasis resulting in disseminated intravascular coagulation. <i>World Journal of Surgical Oncology</i> , 2005 , 3, 29	3.4	3
24	Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. <i>Lung Cancer</i> , 2021 , 153, 35-41	5.9	3
23	Impact of universal immunohistochemistry on Lynch syndrome diagnosis in an Australian colorectal cancer cohort. <i>Internal Medicine Journal</i> , 2019 , 49, 1278-1284	1.6	2
22	Cancer Testis Antigens161-177		2
21	Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report. <i>Clinical Lung Cancer</i> , 2020 , 21, e57-e60	4.9	2
20	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2021 , 154, 113-117	5.9	2
19	Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2736-2751	4.4	2
18	Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.. <i>Biochemical Society Transactions</i> , 2022 ,	5.1	2
17	Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials. <i>Oncology</i> , 2019 , 97, 270-276	3.6	1
16	Combination approaches in NSCLC involving immune checkpoint inhibitors. <i>Lung Cancer Management</i> , 2016 , 5, 163-171	2.6	1
15	Bronchoepidural Fistula in a man with actinomycosis complicated non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1761-2	8.9	1
14	Controversies in the role of radiotherapy in pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2079-2087	4.4	1
13	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2766-2778	4.4	1
12	Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. <i>Hereditary Cancer in Clinical Practice</i> , 2021 , 19, 33	2.3	1
11	The ADAM Trial: Visiting the Road Less Traveled. <i>JAMA Oncology</i> , 2017 , 3, 66-67	13.4	0
10	Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. <i>Lung Cancer</i> , 2021 , 163, 14-18	5.9	0
9	Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.. <i>Cancer Epidemiology</i> , 2021 , 76, 102080	2.8	0

8	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.. <i>International Journal of Clinical Oncology</i> , 2022 , 27, 695-706	4.2	o
7	SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasis.. <i>Pathology</i> , 2022 ,	1.6	o
6	Imaging immunity in patients with cancer using positron emission tomography.. <i>Npj Precision Oncology</i> , 2022 , 6, 24	9.8	o
5	In Reply to Leone. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e22-e23	8.9	
4	Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort?. <i>Clinical Cancer Research</i> , 2018 , 24, 1513-1515	12.9	
3	Testicular metastasis from ALK-rearranged non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2016 , 9, 32-34	2	
2	Attitudes of patients and physicians on repeat biopsies for lung cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017 , 2, 181-202		
1	Should we screen for lung cancer in Australia?. <i>Medical Journal of Australia</i> , 2013 , 199, 586	4	